Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1996;27:1453-1458

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

(Stroke. 1996;27:1453-1458.)
© 1996 American Heart Association, Inc.


Articles

A Randomized Trial of Tirilazad Mesylate in Patients With Acute Stroke (RANTTAS)

The RANTTAS Investigators

the Departments of Neurology and Neurological Surgery, The Virginia Neurological Institute of the University of Virginia (Charlottesville) (Dr Haley, Dr Johnston, and others), and the participating centers of the RANTTAS Investigators.

Correspondence to E. Clarke Haley, Jr, MD, Department of Neurology, Box 394, University of Virginia Health Sciences Center, Charlottesville, VA 22908. E-mail ech@virginia.edu.

Background and Purpose Tirilazad mesylate, a nonglucocorticoid 21-aminosteroid lipid peroxidation inhibitor, has shown promise as a neuroprotectant in experimental models of focal cerebral ischemia.

Methods To test whether early treatment with tirilazad, 6 mg/kg per day for 3 days, would improve functional outcome after acute human stroke, 27 North American centers conducted a prospective, randomized, double-blinded, vehicle-controlled trial in patients with acute stroke treated within 6 hours of onset. The primary outcome measures were disability as measured by the Glasgow Outcome Scale and activities of daily living by the Barthel Index determined 3 months after stroke.

Results From May 1993 through December 1994, 660 patients were randomized. The trial was prematurely terminated on the advice of an independent monitoring committee after review of outcome data at a preplanned interim analysis. In 556 fully eligible patients (276 tirilazad, 280 vehicle), the odds ratio of a favorable outcome in favor of tirilazad was 0.87 (95% confidence interval [CI], 0.60 to 1.25) for the Glasgow Outcome Scale and 0.87 (95% CI, 0.60 to 1.25) for the Barthel Index, after adjustment for imbalances between the groups in preexisting disability, prior stroke, and diabetes.

Conclusions These observations suggest that tirilazad, 6 mg/kg per day for 3 days administered beginning at a median of 4.3 hours after stroke, does not improve overall functional outcome.


Key Words: cerebral ischemia • lipid peroxidation • neuroprotection • stroke, acute




This article has been cited by other articles:


Home page
StrokeHome page
J. R. Marler
NINDS Clinical Trials in Stroke: Lessons Learned and Future Directions
Stroke, December 1, 2007; 38(12): 3302 - 3307.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
N. Sakellaridis and D. Panagopoulos
Significance of Experimental Infarct Size as an Indicator of Therapeutic Efficacy in Humans
Stroke, September 1, 2007; 38(9): e89 - e90.
[Full Text] [PDF]


Home page
StrokeHome page
The Optimising Analysis of Stroke Trials (OAST) Co
Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV)
Stroke, June 1, 2007; 38(6): 1911 - 1915.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. D. Ginsberg
Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era
Stroke, June 1, 2007; 38(6): 1967 - 1972.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Circulation, May 22, 2007; 115(20): e478 - e534.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Stroke, May 1, 2007; 38(5): 1655 - 1711.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
V. Hachinski
Stroke and Vascular Cognitive Impairment: A Transdisciplinary, Translational and Transactional Approach
Stroke, April 1, 2007; 38(4): 1396 - 1396.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. S. Elkins, T. Khatabi, L. Fung, J. Rootenberg, and S. C. Johnston
Recruiting Subjects for Acute Stroke Trials: A Meta-Analysis
Stroke, January 1, 2006; 37(1): 123 - 128.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Y. Y. Palesch, B. C. Tilley, D. L. Sackett, K. C. Johnston, and R. Woolson
Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
Stroke, November 1, 2005; 36(11): 2410 - 2414.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
F. B. Young, C. J. Weir, K. R. Lees, and for the GAIN International Trial Steering Committe
Comparison of the National Institutes of Health Stroke Scale With Disability Outcome Measures in Acute Stroke Trials
Stroke, October 1, 2005; 36(10): 2187 - 2192.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Biol.Home page
D. S. Warner, H. Sheng, and I. Batinic-Haberle
Oxidants, antioxidants and the ischemic brain
J. Exp. Biol., August 15, 2004; 207(18): 3221 - 3231.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath
Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome
Stroke, May 1, 2004; 35(5): 1216 - 1224.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Kwon, A. G. Hartzema, P. W. Duncan, and S. Min-Lai
Disability Measures in Stroke: Relationship Among the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale
Stroke, April 1, 2004; 35(4): 918 - 923.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. C. Johnston, A. F. Connors Jr, D. P. Wagner, and E. C. Haley Jr
Risk Adjustment Effect on Stroke Clinical Trials
Stroke, February 1, 2004; 35 (2): e43 - e45.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Zausinger, K. Scholler, N. Plesnila, and R. Schmid-Elsaesser
Combination Drug Therapy and Mild Hypothermia After Transient Focal Cerebral Ischemia in Rats
Stroke, September 1, 2003; 34(9): 2246 - 2251.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al.
Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association
Stroke, April 1, 2003; 34(4): 1056 - 1083.
[Full Text] [PDF]


Home page
StrokeHome page
K. C. Johnston, A. F. Connors Jr, D. P. Wagner, and E. C. Haley Jr
Predicting Outcome in Ischemic Stroke: External Validation of Predictive Risk Models
Stroke, January 1, 2003; 34(1): 200 - 202.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Mocco, T. Choudhri, J. Huang, E. Harfeldt, L. Efros, C. Klingbeil, V. Vexler, W. Hall, Y. Zhang, W. Mack, et al.
HuEP5C7 as a Humanized Monoclonal Anti-E/P-Selectin Neurovascular Protective Strategy in a Blinded Placebo-Controlled Trial of Nonhuman Primate Stroke
Circ. Res., November 15, 2002; 91(10): 907 - 914.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. C. Johnston, D. P. Wagner, E. C. Haley Jr, and A. F. Connors Jr
Combined Clinical and Imaging Information as an Early Stroke Outcome Measure
Stroke, February 1, 2002; 33(2): 466 - 472.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. L. Sacco, J. T. DeRosa, E. C. Haley Jr, B. Levin, P. Ordronneau, S. J. Phillips, T. Rundek, R. G. Snipes, J. L. P. Thompson, and for the GAIN Americas Investigators
Glycine Antagonist in Neuroprotection for Patients With Acute Stroke: GAIN Americas: A Randomized Controlled Trial
JAMA, April 4, 2001; 285(13): 1719 - 1728.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Uchino, D. Billheimer, and S. C. Cramer
Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials
Stroke, April 1, 2001; 32(4): 909 - 916.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
G. P. Samsa and D. B. Matchar
Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered? : An Illustration of Three Statistical Principles
Stroke, March 1, 2001; 32(3): 669 - 674.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. R. Lees, A. K. Sharma, D. Barer, G. A. Ford, V. Kostulas, Y.-F. Cheng, and T. Odergren
Tolerability and Pharmacokinetics of the Nitrone NXY-059 in Patients With Acute Stroke
Stroke, March 1, 2001; 32(3): 675 - 680.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
R. J. Kavanagh and P. C. A. Kam
Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection
Br. J. Anaesth., January 1, 2001; 86(1): 110 - 119.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. Fisher and W. Schaebitz
An Overview of Acute Stroke Therapy: Past, Present, and Future
Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206.
[Full Text] [PDF]


Home page
StrokeHome page
H. C. Diener, M. Cortens, G. Ford, J. Grotta, W. Hacke, M. Kaste, P. J. Koudstaal, and T. Wessel
Lubeluzole in Acute Ischemic Stroke Treatment : A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo
Stroke, November 1, 2000; 31(11): 2543 - 2551.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
N. Delanty and M. A. Dichter
Antioxidant Therapy in Neurologic Disease
Arch Neurol, September 1, 2000; 57(9): 1265 - 1270.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Tirilazad Mesylate in Acute Ischemic Stroke : A Systematic Review
Stroke, September 1, 2000; 31(9): 2257 - 2265.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
T. E. Mayer, G. F. Hamann, J. Baranczyk, B. Rosengarten, E. Klotz, M. Wiesmann, U. Missler, G. Schulte-Altedorneburg, and H. J. Brueckmann
Dynamic CT Perfusion Imaging of Acute Stroke
AJNR Am. J. Neuroradiol., August 1, 2000; 21(8): 1441 - 1449.
[Abstract] [Full Text]


Home page
StrokeHome page
K. C. Johnston, A. F. Connors Jr, D. P. Wagner, W. A. Knaus, X.-Q. Wang, and E. C. Haley Jr
A Predictive Risk Model for Outcomes of Ischemic Stroke
Stroke, February 1, 2000; 31(2): 448 - 455.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
G DEVUYST and J BOGOUSSLAVSKY
Recent progress in drug treatment for acute stroke
J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 420 - 425.
[Full Text] [PDF]


Home page
StrokeHome page
R. Schmid-Elsaesser, E. Hungerhuber, S. Zausinger, A. Baethmann, H.-J. Reulen, and J. A. Zivin
Combination Drug Therapy and Mild Hypothermia : A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia • Editorial Comment: A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia
Stroke, September 1, 1999; 30 (9): e1891 - 1899.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
M. Davis and D. Barer
Neuroprotection in acute ischaemic stroke. II: Clinical potential
Vascular Medicine, August 1, 1999; 4(3): 149 - 163.
[Abstract] [PDF]


Home page
StrokeHome page
G. Sulter, C. Steen, and Jacques De Keyser
Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials
Stroke, August 1, 1999; 30(8): 1538 - 1541.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. J. DeGraba, J. M. Hallenbeck, K. D. Pettigrew, A. J. Dutka, and B. J. Kelly
Progression in Acute Stroke : Value of the Initial NIH Stroke Scale Score on Patient Stratification in Future Trials
Stroke, June 1, 1999; 30(6): 1208 - 1212.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Berrouschot, H. Barthel, J. Koster, S. Hesse, A. Rossler, W. H. Knapp, and D. Schneider
Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke : A Randomized Pilot Study
Stroke, April 1, 1999; 30(4): 787 - 792.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. L. Saver, K. C. Johnston, D. Homer, R. Wityk, W. Koroshetz, L. L. Truskowski, and E. C. Haley
Infarct Volume as a Surrogate or Auxiliary Outcome Measure in Ischemic Stroke Clinical Trials
Stroke, February 1, 1999; 30(2): 293 - 298.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. C. Haley Jr
High-Dose Tirilazad for Acute Stroke (RANTTAS II)
Stroke, June 1, 1998; 29 (6): 1256 - 1257.
[Full Text]


Home page
JAMAHome page
M. Fisher and J. Bogousslavsky
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA, April 22, 1998; 279(16): 1298 - 1303.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. C. Johnston, J. Y. Li, P. D. Lyden, S. K. Hanson, T. E. Feasby, R. J. Adams, R. E. Faught Jr, and E. C. Haley Jr
Medical and Neurological Complications of Ischemic Stroke : Experience From the RANTTAS Trial
Stroke, February 1, 1998; 29(2): 447 - 453.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. G. Dyker and K. R. Lees
Duration of Neuroprotective Treatment for Ischemic Stroke
Stroke, February 1, 1998; 29(2): 535 - 542.
[Abstract] [Full Text] [PDF]